Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.

Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, Jevremovic D, Altman JK, Patnaik MM.

Am J Hematol. 2019 Jun 7. doi: 10.1002/ajh.25552. [Epub ahead of print] No abstract available.

PMID:
31173385
2.

Copper-imidazo[1,2-a]pyridines induce intrinsic apoptosis and modulate the expression of mutated p53, haem-oxygenase-1 and apoptotic inhibitory proteins in HT-29 colorectal cancer cells.

Harmse L, Gangat N, Martins-Furness C, Dam J, de Koning CB.

Apoptosis. 2019 May 9. doi: 10.1007/s10495-019-01547-7. [Epub ahead of print]

PMID:
31073781
3.

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis.

Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD.

Clin Cancer Res. 2019 May 6. doi: 10.1158/1078-0432.CCR-19-1005. [Epub ahead of print]

PMID:
31061068
4.

Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies.

Tefferi A, Nicolosi M, Penna D, Vallapureddy R, Hanson CA, Pardanani A, Gangat N, Ketterling RP.

Leukemia. 2019 May 1. doi: 10.1038/s41375-019-0453-5. [Epub ahead of print] No abstract available.

PMID:
31040370
5.

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.

Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM.

Am J Hematol. 2019 Jul;94(7):767-779. doi: 10.1002/ajh.25488. Epub 2019 May 3.

PMID:
30964202
6.

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A.

Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022. Epub 2019 Feb 26.

PMID:
30824279
7.

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 25;9(2):12. doi: 10.1038/s41408-019-0175-y.

8.

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Gangat N, Phelps A, Lasho TL, Finke CM, Vallapureddy R, Hanson CA, Ketterling RP, Patnaik MM, Pardanani A, Tefferi A.

Blood Cancer J. 2019 Jan 24;9(2):11. doi: 10.1038/s41408-018-0167-3. No abstract available.

9.

Calculator-free point-of-care prognostication in myelodysplastic syndromes.

Tefferi A, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Apr;94(4):E99-E101. doi: 10.1002/ajh.25400. Epub 2019 Jan 24. No abstract available.

PMID:
30637785
10.

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.

Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A.

Haematologica. 2019 Jun;104(6):e236-e239. doi: 10.3324/haematol.2018.208082. Epub 2019 Jan 3. No abstract available.

11.

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.

Penna D, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2019 Mar;94(3):286-290. doi: 10.1002/ajh.25351. Epub 2018 Dec 5.

PMID:
30516867
12.

The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.

Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Am J Hematol. 2019 Mar;94(3):299-305. doi: 10.1002/ajh.25349. Epub 2018 Dec 5.

PMID:
30516848
13.

MPL-mutated essential thrombocythemia: a morphologic reappraisal.

Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3. No abstract available.

14.

Genetic predictors of response to specific drugs in primary myelofibrosis.

Penna D, Szuber N, Lasho TL, Finke CM, Vallapureddy RR, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):120. doi: 10.1038/s41408-018-0158-4. No abstract available.

15.

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.

Szuber N, Lavu S, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2018 Nov 19;8(12):118. doi: 10.1038/s41408-018-0157-5. No abstract available.

16.

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.

Pardanani A, Shah S, Mannelli F, Elala YC, Guglielmelli P, Lasho TL, Patnaik MM, Gangat N, Ketterling RP, Reichard KK, Hanson CA, Vannucchi AM, Tefferi A.

Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.

17.

Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy.

Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, Alkhateeb HB, Patnaik MS, Hogan WJ, Litzow MR, Al-Kali A.

Ann Hematol. 2019 Feb;98(2):331-337. doi: 10.1007/s00277-018-3509-0. Epub 2018 Oct 18.

PMID:
30334068
18.

Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis.

Szuber N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Leukemia. 2019 Mar;33(3):780-785. doi: 10.1038/s41375-018-0283-x. Epub 2018 Oct 12. No abstract available.

PMID:
30315236
19.

Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.

Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, Litzow MR, Alkhateeb HB.

Leuk Lymphoma. 2019 Apr;60(4):990-999. doi: 10.1080/10428194.2018.1509318. Epub 2018 Oct 2.

PMID:
30277111
20.

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.

Tefferi A, Szuber N, Vallapureddy RR, Begna KH, Patnaik MM, Elliott MA, Christopher Hook C, Wolanskyj AP, Hanson CA, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2019 Jan;94(1):5-9. doi: 10.1002/ajh.25294. Epub 2018 Oct 17.

PMID:
30252953
21.

A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.

Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):E401-E404. doi: 10.1002/ajh.25290. Epub 2018 Oct 17. No abstract available.

PMID:
30230610
22.

Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes.

Alkharabsheh O, Saadeh SS, Patnaik MS, Alkhateeb H, Gangat N, Begna KH, Hogan WJ, Greipp PT, He R, Nguyen PL, Litzow MR, Al-Kali A.

Am J Hematol. 2018 Dec;93(12):E398-E401. doi: 10.1002/ajh.25287. Epub 2018 Oct 9. No abstract available.

PMID:
30218541
23.

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.

Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, Pardanani A, Droin N, Gangat N, Tefferi A, Solary E.

Blood Cancer J. 2018 Aug 22;8(9):82. doi: 10.1038/s41408-018-0120-5. No abstract available.

24.

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.

Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Dec;93(12):1474-1484. doi: 10.1002/ajh.25270. Epub 2018 Sep 27.

PMID:
30157297
25.

Mutations and karyotype predict treatment response in myelodysplastic syndromes.

Idossa D, Lasho TL, Finke CM, Ketterling RP, Patnaik MM, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Nov;93(11):1420-1426. doi: 10.1002/ajh.25267. Epub 2018 Sep 30.

PMID:
30152885
26.

Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, Nagorney D, Tefferi A, Patnaik MM.

Am J Hematol. 2018 Nov;93(11):1347-1357. doi: 10.1002/ajh.25246. Epub 2018 Oct 5.

PMID:
30105755
27.

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels.

Tefferi A, Nicolosi M, Penna D, Mudireddy M, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani AD.

Blood Adv. 2018 Aug 14;2(15):1980-1984. doi: 10.1182/bloodadvances.2018018051. No abstract available.

28.

The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS.

Alkharabsheh O, Al-Kali A, Saadeh S, He R, Viswanatha D, Greipp P, Reichard K, Shah M, Gangat N, Patnaik M, Hogan W, Litzow M, Alkhateeb H, Nguyen PL.

Am J Hematol. 2018 Nov;93(11):E355-E357. doi: 10.1002/ajh.25239. Epub 2018 Oct 2. No abstract available.

PMID:
30074268
29.

Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients.

Higgins A, Mangaonkar AA, Hefazi M, Viswanatha D, Horna P, Foran J, Gangat N.

Leuk Res. 2018 Sep;72:1-4. doi: 10.1016/j.leukres.2018.07.018. Epub 2018 Jul 21. No abstract available.

PMID:
30055376
30.

Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts.

Mangaonkar AA, Gangat N, Al-Kali A, Elliott MA, Begna KH, Hanson CA, Ketterling RP, Wolanskyj-Spinner AP, Hogan WJ, Litzow MR, Patnaik MM.

Leuk Res. 2018 Aug;71:60-62. doi: 10.1016/j.leukres.2018.07.010. Epub 2018 Jul 11.

PMID:
30015104
31.

Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis.

Mudireddy M, Gangat N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Ashrani AA, Pardanani A, Nagorney DM, Tefferi A.

Am J Hematol. 2018 Sep;93(9):E235-E238. doi: 10.1002/ajh.25203. Epub 2018 Aug 31. No abstract available.

PMID:
29981287
32.

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis.

Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.

Blood Cancer J. 2018 Jun 11;8(6):57. doi: 10.1038/s41408-018-0095-2. No abstract available.

33.

Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA.

Mayo Clin Proc. 2018 Oct;93(10):1363-1374. doi: 10.1016/j.mayocp.2018.04.013. Epub 2018 Jun 14.

PMID:
29866419
34.

A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.

Patnaik MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, Hanson CA, Gangat N, Tefferi A, Pardanani A.

Leukemia. 2018 Aug;32(8):1850-1856. doi: 10.1038/s41375-018-0121-1. Epub 2018 Apr 2. No abstract available.

PMID:
29712989
35.

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.

Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM.

J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30. No abstract available.

PMID:
29708808
36.

The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes.

Penna D, Nicolosi M, Vallapureddy RR, Szuber N, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Jul;93(7):E164-E167. doi: 10.1002/ajh.25114. Epub 2018 May 6. No abstract available.

PMID:
29659079
37.

Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.

Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM.

Leuk Lymphoma. 2018 Dec;59(12):2998-3001. doi: 10.1080/10428194.2018.1452212. Epub 2018 Mar 27. No abstract available.

PMID:
29582697
38.

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients.

Nicolosi M, Mudireddy M, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A, Tefferi A.

Leukemia. 2018 May;32(5):1254-1258. doi: 10.1038/s41375-018-0028-x. Epub 2018 Jan 30. No abstract available.

39.

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.

Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Leukemia. 2018 Oct;32(10):2274-2278. doi: 10.1038/s41375-018-0078-0. Epub 2018 Feb 27. No abstract available.

40.

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms.

Lasho TL, Vallapureddy R, Finke CM, Mangaonkar A, Gangat N, Ketterling R, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Mar 12;8(3):32. doi: 10.1038/s41408-018-0057-8. No abstract available.

41.

U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates.

Tefferi A, Mudireddy M, Finke CM, Nicolosi M, Lasho TL, Hanson CA, Patnaik MM, Pardanani A, Gangat N.

Am J Hematol. 2018 Jun;93(6):E146-E148. doi: 10.1002/ajh.25084. Epub 2018 Apr 6. No abstract available.

42.

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Blood Cancer J. 2018 Mar 7;8(3):29. doi: 10.1038/s41408-018-0067-6.

43.

Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia.

Ogden J, Yui J, Ali W, Mudireddy M, Al-Kali A, Patnaik M, Gangat N, Elliott M, Hogan W, Hook C, Wolanskyj-Spinner A, Pardanani A, Villarraga H, Litzow M, Tefferi A, Begna K.

Am J Hematol. 2018 Jun;93(6):E144-E146. doi: 10.1002/ajh.25083. Epub 2018 Apr 11. No abstract available.

44.

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.

Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, Hanson CA, Ketterling RP, Pardanani A.

Leukemia. 2018 May;32(5):1189-1199. doi: 10.1038/s41375-018-0018-z. Epub 2018 Feb 2.

45.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

46.

Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience.

Al-Kali A, Abou Hussein AK, Patnaik M, Zblewski D, Gangat N, Hashmi S, Elliott M, Hogan W, Litzow M.

Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1436705. [Epub ahead of print] No abstract available.

PMID:
29465270
47.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

48.

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.

Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, Litzow MR, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Feb 12;8(2):18. doi: 10.1038/s41408-018-0051-1. No abstract available.

49.

Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.

Gangat N, Mudireddy M, Lasho TL, Finke CM, Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 May;93(5):691-697. doi: 10.1002/ajh.25064. Epub 2018 Feb 24.

50.

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental.

Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, Hanson C, Gangat N, Tefferi A.

Blood Cancer J. 2018 Jan 22;8(1):12. doi: 10.1038/s41408-017-0045-4. No abstract available.

Supplemental Content

Loading ...
Support Center